Treatment-Resistant Depression

Midwest CEPAC
May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Key Dates

Associated Materials

10/10/2018 – 10/30/2018
Open Input Period

10/31/2018

10/31/2018

10/31/2018 – 11/20/2018

11/29/2018

01/14/2019
Research Protocol

02/05/2019
Model Analysis Plan

03/21/2019
Draft Voting Questions

03/21/2019
Draft Evidence Report

03/21/2019 – 04/17/2019
Public Comments

05/09/2019
Evidence Report

05/09/2019
Revised Voting Questions

05/09/2019
Response to Comments

05/23/2019
Meeting Agenda

05/23/2019
Evidence Presentation

06/20/2019
Final Evidence Report and Meeting Summary

06/20/2019
Report-at-a-Glance